| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94573ab2c57e8b193f3a22accddf9fe |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
| filingDate |
2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76bea41e9cf59edebad753b914ec534f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77ade8db811dd769328f5e2124c218bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24e4fed31e1ba01c1be16db6101d3b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca2d4e6fbd360b744141442f2a87de5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93c7a9989a2eea1d6944d390547b09bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9532e3b43217f19218ca236d5ba7bda |
| publicationDate |
2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016303156-A1 |
| titleOfInvention |
Pharmaceutical composition comprising naringin and levocetirizine hydrochloride, and preparations thereof |
| abstract |
A naringin composition and preparations thereof are provided. The pharmaceutical composition comprises naringin and levocetirizine hydrochloride, and preferably, 27.5-275 mg of naringin and 1.25-12.5 mg of levocetirizine hydrochloride, where the preferred weight ratio of naringin to levocetirizine hydrochloride is 20:1. The pharmaceutical composition has good curative effects on cough and sputum production originating from various causes and on cough variant asthma. The efficacy of the pharmaceutical composition is obviously superior to that of naringin or levocetirizine hydrochloride that is used alone. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021004210-A |
| priorityDate |
2014-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |